Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2023-01-18 Capital/Financing Update
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Disc Medicine, Inc. It registers shares of common stock issuable under various employee stock option and purchase plans. The document includes detailed information about the plans, the merger, stock split, and share reserve increases. It is a registration statement related to securities issuance under employee benefit plans, not a financial report, earnings release, or management discussion. Form S-8 filings are capital market filings related to share issuance and employee compensation plans. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed substantive information, not just an announcement or reference to another report.
2023-01-18 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) by Disc Medicine, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for sale to the public. The text includes details about the offering of common stock by selling stockholders, the plan of distribution, risk factors, and other information typical of a registration statement prospectus. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or certification, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2023-01-18 English
FORM 3 SUBMISSION
Director's Dealing
2023-01-09 English
SC 13D
Major Shareholding Notification
2023-01-09 English
NONE
Major Shareholding Notification
2023-01-09 English
AMENDMENT NO. 2 TO SCHEDULE 13D
Major Shareholding Notification
2023-01-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.